Biosenta Inc.
ZRO
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | -42.86% | 24,366.67% | -40.00% | -33.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | -42.86% | 24,366.67% | -40.00% | -33.33% |
| Cost of Revenue | -83.33% | -83.33% | -98.11% | -87.45% | -87.39% |
| Gross Profit | 117.39% | 113.04% | 666.02% | 90.43% | 90.00% |
| SG&A Expenses | -26.16% | -25.79% | -13.96% | 11.97% | 36.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.22% | -26.33% | -14.10% | 10.38% | 25.90% |
| Operating Income | 26.27% | 26.34% | 28.08% | -10.41% | -25.95% |
| Income Before Tax | 64.81% | 65.11% | -1,449.37% | -1,060.69% | -422.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 64.81% | 65.11% | -1,449.37% | -1,060.69% | -422.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.81% | 65.11% | -1,449.37% | -1,060.69% | -422.54% |
| EBIT | 26.27% | 26.34% | 28.08% | -10.41% | -25.95% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 62.24% | 60.69% | -501.07% | -447.38% | -381.99% |
| Normalized Basic EPS | -15.26% | -29.93% | 0.32% | -19.12% | -10.39% |
| EPS Diluted | 62.24% | 60.69% | -501.07% | -447.38% | -381.99% |
| Normalized Diluted EPS | -15.26% | -29.93% | 0.32% | -19.12% | -10.39% |
| Average Basic Shares Outstanding | 11.74% | 9.69% | 38.55% | 31.92% | 31.64% |
| Average Diluted Shares Outstanding | 11.74% | 9.69% | 38.55% | 31.92% | 31.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |